Pfizer announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum.
Danish pharma company H. Lundbeck has agreed to acquire Abide Therapeutics, a US-based clinical-stage biopharma company, in a deal worth up to $400m.
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases announces the signing of a collaborative research, option and exclusive license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates.
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precision medicine collaboration in oncology.
Tmunity Therapeutics has entered into an exclusive licensing and research collaboration with the University of California San Francisco (UCSF) aimed at advancing novel engineered T Cell Receptor (TCR) therapies for rare and currently incurable pediatric conditions with high mortality rates.
Japan-based Takeda Pharmaceutical has opened a new 165,000ft² global research facility in San Diego of California, US.
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar.
AstraZeneca has commenced a long-term collaboration with BenevolentAI to tap into the latter’s artificial intelligence (AI) and machine learning technology to accelerate discovery of new drugs for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
French start-up company Iktos has entered into a research collaboration with Janssen Pharmaceutica to deploy its artificial intelligence (AI) technology to help the latter increase speed and efficiency of its small molecule drug discovery.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.